These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 30667319)

  • 1. Demyelinating lesions behaving like aggressive tumours on advanced MRI techniques.
    Barbosa BC; Marchiori E; Leal Leidersnaider C; Brandao L; Castillo M
    Neuroradiol J; 2019 Apr; 32(2):103-107. PubMed ID: 30667319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combining Diffusion Tensor Metrics and DSC Perfusion Imaging: Can It Improve the Diagnostic Accuracy in Differentiating Tumefactive Demyelination from High-Grade Glioma?
    Hiremath SB; Muraleedharan A; Kumar S; Nagesh C; Kesavadas C; Abraham M; Kapilamoorthy TR; Thomas B
    AJNR Am J Neuroradiol; 2017 Apr; 38(4):685-690. PubMed ID: 28209583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MRI Findings in Tumefactive Demyelinating Lesions: A Systematic Review and Meta-Analysis.
    Suh CH; Kim HS; Jung SC; Choi CG; Kim SJ
    AJNR Am J Neuroradiol; 2018 Sep; 39(9):1643-1649. PubMed ID: 30115676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Solitary Tumefactive Demyelinating Lesions in Children: Clinical and Magnetic Resonance Imaging Features, Pathologic Characteristics, and Outcomes.
    Frankl S; Viaene A; Vossough A; Waldman A; Hopkins S; Banwell B
    Pediatr Neurol; 2024 Aug; 157():141-150. PubMed ID: 38917518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Performance of Apparent Diffusion Coefficient Values and Conventional MRI Features in Differentiating Tumefactive Demyelinating Lesions From Primary Brain Neoplasms.
    Mabray MC; Cohen BA; Villanueva-Meyer JE; Valles FE; Barajas RF; Rubenstein JL; Cha S
    AJR Am J Roentgenol; 2015 Nov; 205(5):1075-85. PubMed ID: 26496556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and imaging correlation in patients with pathologically confirmed tumefactive demyelinating lesions.
    Tremblay MA; Villanueva-Meyer JE; Cha S; Tihan T; Gelfand JM
    J Neurol Sci; 2017 Oct; 381():83-87. PubMed ID: 28991721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conventional and advanced magnetic resonance imaging in tumefactive demyelination.
    Saini J; Chatterjee S; Thomas B; Kesavadas C
    Acta Radiol; 2011 Dec; 52(10):1159-68. PubMed ID: 22025739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumefactive demyelinating lesion: experience with two unusual patients.
    Sinha MK; Garg RK; Bhatt ML; Chandra A
    J Postgrad Med; 2010; 56(2):146-9. PubMed ID: 20622396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can permeability measurements add to blood volume measurements in differentiating tumefactive demyelinating lesions from high grade gliomas using perfusion CT?
    Jain R; Ellika S; Lehman NL; Scarpace L; Schultz LR; Rock JP; Rosenblum M; Mikkelsen T
    J Neurooncol; 2010 May; 97(3):383-8. PubMed ID: 19830525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Solitary tumefactive demyelinating lesions in children.
    Morin MP; Patenaude Y; Sinsky AB; Banwell B; Sébire G
    J Child Neurol; 2011 Aug; 26(8):995-9. PubMed ID: 21555780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imaging of Fulminant Demyelinating Disorders of the Central Nervous System.
    Razek AAKA; Elsebaie NA
    J Comput Assist Tomogr; 2020; 44(2):248-254. PubMed ID: 32195804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and magnetic resonance imaging (MRI) distinctions between tumefactive demyelination and brain tumors in children.
    Yiu EM; Laughlin S; Verhey LH; Banwell BL;
    J Child Neurol; 2014 May; 29(5):654-65. PubMed ID: 24092896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumefactive demyelinating lesions.
    Dagher AP; Smirniotopoulos J
    Neuroradiology; 1996 Aug; 38(6):560-5. PubMed ID: 8880719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Demyelination preceding a diagnosis of central nervous system lymphoma.
    Kalus S; Di Muzio B; Gaillard F
    J Clin Neurosci; 2016 Feb; 24():146-8. PubMed ID: 26455545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proton magnetic resonance spectroscopy differentiates tumefactive demyelinating lesions from gliomas.
    Ikeguchi R; Shimizu Y; Abe K; Shimizu S; Maruyama T; Nitta M; Abe K; Kawamata T; Kitagawa K
    Mult Scler Relat Disord; 2018 Nov; 26():77-84. PubMed ID: 30237108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo evolution of biopsy-proven inflammatory demyelination quantified by R2t* mapping.
    Xiang B; Wen J; Lu HC; Schmidt RE; Yablonskiy DA; Cross AH
    Ann Clin Transl Neurol; 2020 Jun; 7(6):1055-1060. PubMed ID: 32367692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumefactive demyelinating lesions: conventional and advanced magnetic resonance imaging.
    Enzinger C; Strasser-Fuchs S; Ropele S; Kapeller P; Kleinert R; Fazekas F
    Mult Scler; 2005 Apr; 11(2):135-9. PubMed ID: 15794384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumefactive demyelinating lesions (TDLs): A case series of clinicoradiological features.
    Jain RS; Khan I; Kandelwal K; Desai T
    Clin Neurol Neurosurg; 2017 Nov; 162():91-94. PubMed ID: 28987645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Magnetic resonance imaging features of solitary inflammatory brain masses.
    Bakshi R; Glass J; Louis DN; Hochberg FH
    J Neuroimaging; 1998 Jan; 8(1):8-14. PubMed ID: 9442584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploring the overlap between multiple sclerosis, tumefactive demyelination and Baló's concentric sclerosis.
    Hardy TA; Tobin WO; Lucchinetti CF
    Mult Scler; 2016 Jul; 22(8):986-92. PubMed ID: 27037180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.